Table 2.

Comparison of pharmacokinetic parameters of chlorpropamide after single oral administration of 250 mg chlorpropamide to subjects with different CYP2C9 and CYP2C19 genotypes

	CYP2C19		CYP2C9
EMa (n = 6)	PMb (n = 7)	*1/*1 (n = 13)	*1/*3 (n = 8)
Cmax (µg ml−1)	27.9 ± 1.6	31.0 ± 2.6	29.6 ± 1.6	31.7 ± 1.8
t1/2 (h)	35.8 ± 2.4	38.9 ± 2.2	37.5 ± 1.6	39.4 ± 4.2
CL/F (ml h−1 kg−1)	2.9 ± 0.1	2.7 ± 0.1	2.8 ± 0.1	2.7 ± 0.3
CLNR (ml h−1 kg−1)c	2.5 ± 0.1	2.3 ± 0.1	2.4 ± 0.1	1.8 ± 0.2*
Vd/F (ml kg−1)	146.4 ± 3.7	151.6 ± 7.2	149.2 ± 4.2	141.8 ± 11.0
AUCinf (µg ml−1 h−1)	1360.7 ± 53.0	1454.2 ± 96.6	1411.0 ± 56.6	1628.0 ± 129.6
Metabolic ratiod	0.71 ± 0.14	0.43 ± 0.07	0.56 ± 0.08	1.01 ± 0.19*

Each value indicates mean ± SE.

^aEM of CYP2C19; CYP2C19*1/*1.

^bPM of CYP2C19; CYP2C19*2/*2, *3/*3, or *2/*3.

^cCL_NR, Nonrenal clearance.

^*P < 0.05; unpaired t-test between subjects with different CYP2C9 genotypes.

^dMetabolic ratio = chlorpropamide/2-OH-chlorpropamide molar amount in urine for 24 h after dosing.